Andrew James Doyle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew James Doyle has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Beverley Jane Hunt
Guy's and St Thomas' NHS Foundation Trust, London, UK
7 shared publications Karen A. Breen
Department of Haemostasis & Thrombosis Guy's & St Thomas' NHS Foundation Trust London UK
6 shared publications- Andrew Retter
Critical Care Department, Guy’s and St Thomas NHS Foundation Trust, London, United Kingdom
3 shared publications Anicee Danaee
Haemostasis and Thrombosis Centre St Thomas’ Hospital London UK
3 shared publicationsBeverley J. Hunt
Haemostasis and Thrombosis Centre St Thomas’ Hospital London UK
3 shared publicationsMarie Scully
University College London Hospitals NHS Foundation Trust, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy
Background: Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim: To compare thrombotic and safety outcomes in patients receiving either vitamin K antagonists (VKAs) or apixaban 2.5 mg twice daily in the context of ESRD and RRT. Method: Retrospective service evaluation comparing bleeding and thrombotic outcomes in patients treated with apixaban 2.5 mg BD or VKA in a tertiary anticoagulation clinic. Trough anti‐Xa levels of apixaban patients were reviewed. Clinical features and outcomes were reviewed using electronic patient records. Results: Fifty‐five VKA and 33 apixaban patients were included in the analysis. There were no major bleeds in the apixaban cohort compared with 4 (7.3%) in the VKA cohort ( χ 2 = 2.667, p = 0.102). No difference in time to major or clinically relevant non‐major bleeding (CRNMB) was found ( χ 2 = 1.252, p = 0.263). Rates of thrombotic events (all stroke) were 1 vs . 3 (1.1 and 7.1 events/100 patient‐years) for VKA and apixaban, respectively ( χ 2 = 3.291, p = 0.070). Only one stroke was related to AF. Eighty‐four of 85 trough anti‐Xa levels analysed were below the upper limit of normal of the reference range for the general population. Discussion: Our results suggest similar outcomes with VKA and apixaban in those receiving RRT, indicating apixaban may be a viable second‐line treatment option in those for whom VKA may not be appropriate. Further investigation into the safety of the apixaban 5‐mg regimen is warranted.
- 4 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessComparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy
Background: Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim: To compare thrombotic and safety outcomes in patients receiving either vitamin K antagonists (VKAs) or apixaban 2.5 mg twice daily in the context of ESRD and RRT. Method: Retrospective service evaluation comparing bleeding and thrombotic outcomes in patients treated with apixaban 2.5 mg BD or VKA in a tertiary anticoagulation clinic. Trough anti‐Xa levels of apixaban patients were reviewed. Clinical features and outcomes were reviewed using electronic patient records. Results: Fifty‐five VKA and 33 apixaban patients were included in the analysis. There were no major bleeds in the apixaban cohort compared with 4 (7.3%) in the VKA cohort ( χ 2 = 2.667, p = 0.102). No difference in time to major or clinically relevant non‐major bleeding (CRNMB) was found ( χ 2 = 1.252, p = 0.263). Rates of thrombotic events (all stroke) were 1 vs . 3 (1.1 and 7.1 events/100 patient‐years) for VKA and apixaban, respectively ( χ 2 = 3.291, p = 0.070). Only one stroke was related to AF. Eighty‐four of 85 trough anti‐Xa levels analysed were below the upper limit of normal of the reference range for the general population. Discussion: Our results suggest similar outcomes with VKA and apixaban in those receiving RRT, indicating apixaban may be a viable second‐line treatment option in those for whom VKA may not be appropriate. Further investigation into the safety of the apixaban 5‐mg regimen is warranted.
- Open Access
- 14 May 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (8) , 2946-2956
Prevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis
- 14 May 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (8) , 2946-2956
Open AccessPrevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis
- Open Access
- 17 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Antiphospholipid syndrome and pregnancy—a hematologic perspective
- 17 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Open AccessAntiphospholipid syndrome and pregnancy—a hematologic perspective
- Open Access
- 6 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (1)
Unlucky for some? Bleeding associated with factor XIII deficiency during extracorporeal membrane oxygenation
- 6 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (1)
Open AccessUnlucky for some? Bleeding associated with factor XIII deficiency during extracorporeal membrane oxygenation
- Open Access
Common Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of Practice
Introduction: Secondary and idiopathic polycythaemia is far more common than polycythaemia vera. Whilst venesection for polycythaemia vera has a robust evidence base, the data supporting this treatment for secondary and/or idiopathic polycythaemia are limited to small single‐arm studies showing transient improvement in symptoms or physiologic endpoints. As a result the British Society for Haematology Guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis suggests considering venesection in patients with hypoxic lung disease with Hct > 0.56 or to a target Hct < 0.55 in those with idiopathic polycythaemia. We hypothesised that this paucity of evidence results in widespread variation in management of secondary polycythaemia. Methods: To assess attitudes and practice in the treatment of secondary and idiopathic polycythaemia we designed an international clinician survey to evaluate current practice and define the point of clinical equipoise at which clinicians would be content to enter patients into a randomised venesection study. This survey was distributed using the wide‐reaching HaemSTAR research network. Results: A total of 123 clinicians responded, of which 90 were experienced senior clinicians. 62% reported not routinely offering regular venesection whereas 38% of respondents did. Those considering venesection rose to ∼2/3 of respondents in specific circumstances such as polycythaemia‐related symptoms, previous arterial or unprovoked venous thrombosis. Respondents were more likely to offer venesection to patients with idiopathic‐ compared to androgen‐ or hypoxia‐driven polycythaemia. Of those who would venesect, most would use a threshold Hct ≥ 0.55, with a target Hct < 0.55 but there was significant variability. Conclusions: Our survey showed considerable variability in venesection practice for patients with secondary or idiopathic polycythaemia, probably reflecting the paucity of the evidence base. There was widespread support for a trial of venesection vs observation in secondary polycythaemia and this survey has helped to define the threshold Hct at which clinical equipoise exists.
Open AccessCommon Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of Practice
Introduction: Secondary and idiopathic polycythaemia is far more common than polycythaemia vera. Whilst venesection for polycythaemia vera has a robust evidence base, the data supporting this treatment for secondary and/or idiopathic polycythaemia are limited to small single‐arm studies showing transient improvement in symptoms or physiologic endpoints. As a result the British Society for Haematology Guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis suggests considering venesection in patients with hypoxic lung disease with Hct > 0.56 or to a target Hct < 0.55 in those with idiopathic polycythaemia. We hypothesised that this paucity of evidence results in widespread variation in management of secondary polycythaemia. Methods: To assess attitudes and practice in the treatment of secondary and idiopathic polycythaemia we designed an international clinician survey to evaluate current practice and define the point of clinical equipoise at which clinicians would be content to enter patients into a randomised venesection study. This survey was distributed using the wide‐reaching HaemSTAR research network. Results: A total of 123 clinicians responded, of which 90 were experienced senior clinicians. 62% reported not routinely offering regular venesection whereas 38% of respondents did. Those considering venesection rose to ∼2/3 of respondents in specific circumstances such as polycythaemia‐related symptoms, previous arterial or unprovoked venous thrombosis. Respondents were more likely to offer venesection to patients with idiopathic‐ compared to androgen‐ or hypoxia‐driven polycythaemia. Of those who would venesect, most would use a threshold Hct ≥ 0.55, with a target Hct < 0.55 but there was significant variability. Conclusions: Our survey showed considerable variability in venesection practice for patients with secondary or idiopathic polycythaemia, probably reflecting the paucity of the evidence base. There was widespread support for a trial of venesection vs observation in secondary polycythaemia and this survey has helped to define the threshold Hct at which clinical equipoise exists.
- Open Access
Longitudinal assessment of cerebral infarcts and small vessel disease using magnetic resonance imaging in antiphospholipid syndrome: A single‐centre retrospective study
Introduction: Stroke is the most frequent arterial thrombosis in antiphospholipid syndrome (APS) with high rates of recurrence.Methods and patients: A retrospective, single‐centre 10‐year review of patients with APS having sequential cerebral magnetic resonance imaging (MRI) was performed to describe ischaemic features in APS and associated disease risk factors and progression over time.Results: A total of 120 patients and 307 scans were included with 67% of patients receiving vitamin K antagonists (VKA). Note that 65% of patients had baseline ischaemic features with white matter hyperintensities (WMH), as a feature of small vessel disease (SVD), seen in 79% of abnormal scans. Fifteen percent of patients had progressive ischaemic changes with 83% demonstrating progressive WMH and 33% new infarcts (predominantly lacunar) on sequential scans. Progression‐free survival for progressive ischaemia was 88% at 5 years. Multivariate analysis showed longer follow‐up was a risk for developing progressive ischaemia (odds ratio [OR] 1.43, 95% confidence interval [CI] 1.13–1.86, p = 0.005). Hypertension (56% vs. 30%, p = 0.04) and ischaemic heart disease (22% vs. 6%, p = 0.04) were more prevalent with progressive ischaemia. There was no difference in progression or bleeding events according to VKA therapeutic intensity.Discussion: These results show SVD is a common feature of APS using MRI with progressive changes despite anticoagulation. Traditional risk factors for cerebrovascular disease were associated with progression.
Open AccessLongitudinal assessment of cerebral infarcts and small vessel disease using magnetic resonance imaging in antiphospholipid syndrome: A single‐centre retrospective study
Introduction: Stroke is the most frequent arterial thrombosis in antiphospholipid syndrome (APS) with high rates of recurrence.Methods and patients: A retrospective, single‐centre 10‐year review of patients with APS having sequential cerebral magnetic resonance imaging (MRI) was performed to describe ischaemic features in APS and associated disease risk factors and progression over time.Results: A total of 120 patients and 307 scans were included with 67% of patients receiving vitamin K antagonists (VKA). Note that 65% of patients had baseline ischaemic features with white matter hyperintensities (WMH), as a feature of small vessel disease (SVD), seen in 79% of abnormal scans. Fifteen percent of patients had progressive ischaemic changes with 83% demonstrating progressive WMH and 33% new infarcts (predominantly lacunar) on sequential scans. Progression‐free survival for progressive ischaemia was 88% at 5 years. Multivariate analysis showed longer follow‐up was a risk for developing progressive ischaemia (odds ratio [OR] 1.43, 95% confidence interval [CI] 1.13–1.86, p = 0.005). Hypertension (56% vs. 30%, p = 0.04) and ischaemic heart disease (22% vs. 6%, p = 0.04) were more prevalent with progressive ischaemia. There was no difference in progression or bleeding events according to VKA therapeutic intensity.Discussion: These results show SVD is a common feature of APS using MRI with progressive changes despite anticoagulation. Traditional risk factors for cerebrovascular disease were associated with progression.
- 16 September 2024
- Published by SAGE Publications in Lupus
- Vol. 33 (13) , 1446-1454
Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome
Introduction: Vitamin-K antagonists (VKA) are considered the first-line anticoagulants for thrombotic antiphospholipid syndrome (TAPS), particularly with triple positivity or arterial events. However, thrombotic recurrence remains high despite anticoagulation and other clinical issues may arise. Long-term parenteral anticoagulants may therefore be considered, however little is known about the viability of fondaparinux in this setting. Materials and Methods: We describe the efficacy and safety of long-term fondaparinux for TAPS (>3-months duration) treated at a single centre in the UK. Clinical features and the outcomes of recurrence and bleeding were reviewed using electronic patient records. Results: 46 patients were identified with history of either venous or arterial TAPS and a total 175 patient-years using fondaparinux (median duration 2.7 years/patient (IQR 1.4–4.8)). 43 (93%) had VKA as first-line anticoagulation with a median duration of 6.5 years (IQR 4.0 – 9.8). All patients received fondaparinux as second-to fourth-line anticoagulation. Thrombosis recurrence occurred in 1 (1%) patient (0.6 events/100-patient years). Major, clinically relevant non-major (CRNM) or minor bleeding occurred in 2 (7%), 5 (10.9%) and 8 (17.4%) patients respectively. Major/CRNM bleeding rates were 1.1 and 2.9 events/100-patient-years. Age >65years was associated with bleeding ( p = .047) and concurrent antiplatelets were associated with major/CRNM bleeding ( p = .011). Logistic regression showed increasing age was associated with bleeding (OR = 1.097, p = .009). Conclusions: We suggest that fondaparinux may be used for TAPS when VKA is not appropriate. Thrombotic recurrence was infrequent, and the number of major bleeding events appeared comparable to conventional therapies.
- 16 September 2024
- Published by SAGE Publications in Lupus
- Vol. 33 (13) , 1446-1454
Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome
Introduction: Vitamin-K antagonists (VKA) are considered the first-line anticoagulants for thrombotic antiphospholipid syndrome (TAPS), particularly with triple positivity or arterial events. However, thrombotic recurrence remains high despite anticoagulation and other clinical issues may arise. Long-term parenteral anticoagulants may therefore be considered, however little is known about the viability of fondaparinux in this setting. Materials and Methods: We describe the efficacy and safety of long-term fondaparinux for TAPS (>3-months duration) treated at a single centre in the UK. Clinical features and the outcomes of recurrence and bleeding were reviewed using electronic patient records. Results: 46 patients were identified with history of either venous or arterial TAPS and a total 175 patient-years using fondaparinux (median duration 2.7 years/patient (IQR 1.4–4.8)). 43 (93%) had VKA as first-line anticoagulation with a median duration of 6.5 years (IQR 4.0 – 9.8). All patients received fondaparinux as second-to fourth-line anticoagulation. Thrombosis recurrence occurred in 1 (1%) patient (0.6 events/100-patient years). Major, clinically relevant non-major (CRNM) or minor bleeding occurred in 2 (7%), 5 (10.9%) and 8 (17.4%) patients respectively. Major/CRNM bleeding rates were 1.1 and 2.9 events/100-patient-years. Age >65years was associated with bleeding ( p = .047) and concurrent antiplatelets were associated with major/CRNM bleeding ( p = .011). Logistic regression showed increasing age was associated with bleeding (OR = 1.097, p = .009). Conclusions: We suggest that fondaparinux may be used for TAPS when VKA is not appropriate. Thrombotic recurrence was infrequent, and the number of major bleeding events appeared comparable to conventional therapies.
- 5 August 2024
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 125 (04) , 379-384
The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center
Individuals with inherited antithrombin deficiency (IATD) have a high risk of venous thromboembolism (VTE). Most VTEs are managed with direct oral anticoagulants (DOACs), but the utility of DOACs in antithrombin deficiency (ATD) is unreported.Patients with IATD treated with DOAC were identified from our institutions' IATD registry. We assessed patients' characteristics, ATD type, and initial VTE characteristics, thrombosis recurrence and bleeding rates.Thirty-three patients received DOACs for 73 (38.5–111.5) months (median (interquartile range)). Prior to taking DOACs, 12 (36%) patients had VTE recurrence: these occurred after anticoagulation was ceased (4), nonadherence to VKA prior to DOAC use (3), or during heparin use in pregnancy (5). There were no VTE recurrences on standard-dose DOAC, except in a noncompliant patient receiving dabigatran. There was one recurrence with compliant DOAC use—a patient receiving rivaroxaban 10 mg. Six (18%) patients experienced clinically relevant bleeding, which was predominantly menorrhagia (5/6). One major bleeding event, intracranial hemorrhage, occurred in a patient receiving full-dose rivaroxaban who had refractory hypertension (0.5 events/100 patient-years). In this cohort, compliant DOAC users had an overall VTE recurrence rate of 0.5/100 patient-years, whereas with low-dose DOACs the event rate was 3.5/100 patient-years.Standard-dose DOACs appear efficacious and relatively safe in IATD.
- 5 August 2024
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 125 (04) , 379-384
The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center
Individuals with inherited antithrombin deficiency (IATD) have a high risk of venous thromboembolism (VTE). Most VTEs are managed with direct oral anticoagulants (DOACs), but the utility of DOACs in antithrombin deficiency (ATD) is unreported.Patients with IATD treated with DOAC were identified from our institutions' IATD registry. We assessed patients' characteristics, ATD type, and initial VTE characteristics, thrombosis recurrence and bleeding rates.Thirty-three patients received DOACs for 73 (38.5–111.5) months (median (interquartile range)). Prior to taking DOACs, 12 (36%) patients had VTE recurrence: these occurred after anticoagulation was ceased (4), nonadherence to VKA prior to DOAC use (3), or during heparin use in pregnancy (5). There were no VTE recurrences on standard-dose DOAC, except in a noncompliant patient receiving dabigatran. There was one recurrence with compliant DOAC use—a patient receiving rivaroxaban 10 mg. Six (18%) patients experienced clinically relevant bleeding, which was predominantly menorrhagia (5/6). One major bleeding event, intracranial hemorrhage, occurred in a patient receiving full-dose rivaroxaban who had refractory hypertension (0.5 events/100 patient-years). In this cohort, compliant DOAC users had an overall VTE recurrence rate of 0.5/100 patient-years, whereas with low-dose DOACs the event rate was 3.5/100 patient-years.Standard-dose DOACs appear efficacious and relatively safe in IATD.
- 25 July 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 984-992
Temporal changes in markers of coagulation and fibrinolysis in adults during extracorporeal membrane oxygenation
Introduction: Bleeding and thrombotic events (BTE) are frequent during extracorporeal membrane oxygenation (ECMO). They occur at varying timepoints and may be affected by temporal changes in coagulation and fibrinolysis. We aimed to assess various coagulation and fibrinolytic markers over time and their relationship with BTE. Methods: A single-centre prospective study was performed in 17 patients with severe respiratory failure receiving veno-venous ECMO. Blood samples were collected before and during ECMO, and around circuit decannulation. Results: Prior to ECMO, D-Dimer, Plasmin-Antiplasmin complexes (PAP), Plasminogen-Activator Inhibitor-1 (PAI-1) and fibrinogen were elevated. There was an increase in D-Dimer and Prothrombin Fragments 1+2 (PF1+2) (729 to 1305pmol/L, p = .034) by day 1 and PAP increased by day 2 from baseline levels (median 1022 to 1797 µg/L, p = .023). There was a strong positive correlation in PAP, PF1+2 and thrombin-antithrombin complexes (TAT) to D-Dimer. BTE were frequent – 18% had major extracranial haemorrhage and 24% had intracranial haemorrhage. Over time, there was a progressive elevation PAP in patients developing subsequent extracranial haemorrhage, whereas D-Dimer, PAP and PF1+2 increased after intracranial haemorrhage. Conclusions: There were early changes in coagulation activity during ECMO by PF1+2 followed by subsequent fibrinolysis by PAP. Changes in PAP, PF1+2 and TAT were associated with major haemorrhage.
- 25 July 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 984-992
Temporal changes in markers of coagulation and fibrinolysis in adults during extracorporeal membrane oxygenation
Introduction: Bleeding and thrombotic events (BTE) are frequent during extracorporeal membrane oxygenation (ECMO). They occur at varying timepoints and may be affected by temporal changes in coagulation and fibrinolysis. We aimed to assess various coagulation and fibrinolytic markers over time and their relationship with BTE. Methods: A single-centre prospective study was performed in 17 patients with severe respiratory failure receiving veno-venous ECMO. Blood samples were collected before and during ECMO, and around circuit decannulation. Results: Prior to ECMO, D-Dimer, Plasmin-Antiplasmin complexes (PAP), Plasminogen-Activator Inhibitor-1 (PAI-1) and fibrinogen were elevated. There was an increase in D-Dimer and Prothrombin Fragments 1+2 (PF1+2) (729 to 1305pmol/L, p = .034) by day 1 and PAP increased by day 2 from baseline levels (median 1022 to 1797 µg/L, p = .023). There was a strong positive correlation in PAP, PF1+2 and thrombin-antithrombin complexes (TAT) to D-Dimer. BTE were frequent – 18% had major extracranial haemorrhage and 24% had intracranial haemorrhage. Over time, there was a progressive elevation PAP in patients developing subsequent extracranial haemorrhage, whereas D-Dimer, PAP and PF1+2 increased after intracranial haemorrhage. Conclusions: There were early changes in coagulation activity during ECMO by PF1+2 followed by subsequent fibrinolysis by PAP. Changes in PAP, PF1+2 and TAT were associated with major haemorrhage.